What’s New for Newly Diagnosed Multiple Myeloma | Rahul Banerjee, MD, FACP

What’s New for Newly Diagnosed Multiple Myeloma | Rahul Banerjee, MD, FACP
What’s New for Newly Diagnosed Multiple Myeloma | Rahul Banerjee, MD, FACP
ReKInDLE study: Iberdomide Quadruplet Shows Promising Results | Benjamin Diamond, MD
ReKInDLE study: Iberdomide Quadruplet Shows Promising Results | Benjamin Diamond, MD
IMMUNOPLANT-Will Linvoseltamab Consolidation Replace ASCT? | Dickran Kazandjian, MD
IMMUNOPLANT-Will Linvoseltamab Consolidation Replace ASCT? | Dickran Kazandjian, MD
IMerge Phase 3: Long-Term Results of Imetelstat in Lower-Risk MDS | Valeria Santini, MD
IMerge Phase 3: Long-Term Results of Imetelstat in Lower-Risk MDS | Valeria Santini, MD
Optimal 2nd-Line Treatment for CLL? GAIA/CLL13 Findings | Carsten Niemann, MD
Optimal 2nd-Line Treatment for CLL? GAIA/CLL13 Findings | Carsten Niemann, MD
Treating High Risk Smoldering Multiple Myeloma- Aquila Updates | Natalie Callander, MD
Treating High Risk Smoldering Multiple Myeloma- Aquila Updates | Natalie Callander, MD
Your Voice Matters: The Power of Patient-Reported Outcomes in Myeloma | Fabio Efficace, PhD
Your Voice Matters: The Power of Patient-Reported Outcomes in Myeloma | Fabio Efficace, PhD
Updates -Smoldering Multiple Myeloma from ASH 2025 | Rahul Banerjee, MD, FACP
Updates -Smoldering Multiple #Myeloma from ASH 2025 | Rahul Banerjee, MD, FACP
Anito-cel (a BCMA CAR-T) : Shows No Cases of Delayed Neurotoxicity | Natalie Callander, MD
Anito-cel (a BCMA CAR-T) : Shows No Cases of Delayed Neurotoxicity | Natalie Callander, MD
S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD
S100A8 -a new target to prevent T cell exhaustion BsAbs in myeloma | Adolfo Aleman, PhD
Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc
Fewer Bone Marrow Biopsies? Using Blood & Whole Genome Sequencing | Chrissy Baker, MSc